Efficacy and tolerability of once‐monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once‐monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Reginster, J‐Y, Adami, S, Lakatos, P, Greenwald, M, Stepan, J J, Silverman, S L, Christiansen, C, Rowell, L, Mairon, N, Bonvoisin, B, Drezner, M K, Emkey, R, Felsenberg, D, Cooper, C, Delmas, P D, Miller, P D
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2006
Matèries:
Extended Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798147/
https://ncbi.nlm.nih.gov/pubmed/16339289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044958
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars